Compare Lennar Corporation (LEN) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lennar Corporation vs Natera Inc. Common Stock — how do they compare? Lennar Corporation trades at $73.88 (market cap $17.81B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 3.2× Lennar Corporation's market cap, and Lennar Corporation pays a 2.67% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lennar Corporation for 67 Days and Natera Inc. Common Stock for 0 Days on average.
| LEN | NTRA | |
|---|---|---|
Market Cap | $17.81B | $57.03B |
Volume | 4,102,017 | 1,131,157 |
Sector | Consumer Cyclical | Health |
52-Week High | $133.13 | $425.64 |
52-Week Low | $73.53 | $179.42 |
Typical Hold Time | 67 Days | 0 Days |
Enterprise Value | $22.23B | $56.18B |
Dividend Yield | 2.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lennar (LEN) trades at $73.53, down 1.5% on the day, with a bearish technical signal and recent earnings misses. The homebuilder shows declining revenue and profit margins, with 2025 revenue at $34.19B and net income of $2.08B. Valuation metrics appear attractive with P/E of 14.19 and P/B of 0.83, but cash flow trends show negative net cash flow of -$1.16B in 2025. Berkshire Hathaway has been accumulating shares, building an 11.2% stake as of October 2026.
Lennar presents a value opportunity with below-book valuation and strong institutional interest, but faces headwinds from declining profitability, negative cash flow, and housing market challenges. The stock trades below the $77.38 consensus price target, offering potential upside if operational improvements materialize, though execution risks and macroeconomic pressures remain concerns.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
